Clinical and pharmacological evaluation of different preparations of oral erythromycin. 1979

J P Butzler, and R Vanhoof, and N Clumeck, and P de Mol, and M P Vanderlinden, and E Yourassowsky

The activity of erythromycin stearate in respiratory tract infections was evaluated. This study involved 269 out-patients. Of these, 76 satisfied the strict criteria for detailed bacteriological study with positive cultures of a known pathogen before treatment and bacteriological follow-up after treatment. The results of erythromycin stearate were good against the haemolytic streptococcal infections. The activity of this antibiotic was shown to be insufficient against Haemophilus influenzae. A second clinical trial with 20 patients with acute exacerbations of chronic bronchitis demonstrated quite good activity from erythromycin ethylsuccinate and no intolerance when administered in a dose of 1 g q.i.d. The administration of 1 g of the ethylsuccinate immediately after a meal gave a peak serum concentration after 60 min of 3.36 micrograms/ml. Blood levels on the fourth day of this treatment showed some accumulation, concentrations of greater than 4 micrograms/ml being found at 30, 60 and 90 min after the dose. With its good absorption, its lack of toxicity and its reputation for good diffusion into bronchial secretions, we consider that erythromycin ethylsuccinate should have a major place in the treatment of respiratory tract infections.

UI MeSH Term Description Entries
D012141 Respiratory Tract Infections Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases. Respiratory System Infections,Upper Respiratory Tract Infection,Upper Respiratory Tract Infections,Infections, Respiratory,Infections, Respiratory Tract,Infections, Upper Respiratory,Infections, Upper Respiratory Tract,Respiratory Infections,Upper Respiratory Infections,Infection, Respiratory System,Infection, Respiratory Tract,Respiratory Infection, Upper,Respiratory System Infection,Respiratory Tract Infection
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D004917 Erythromycin A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. Erycette,Erymax,Erythromycin A,Erythromycin C,Erythromycin Lactate,Erythromycin Phosphate,Ilotycin,T-Stat,Lactate, Erythromycin,Phosphate, Erythromycin,T Stat,TStat
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006193 Haemophilus influenzae A species of HAEMOPHILUS found on the mucous membranes of humans and a variety of animals. The species is further divided into biotypes I through VIII. Bacterium influenzae,Coccobacillus pfeifferi,Haemophilus meningitidis,Hemophilus influenzae,Influenza-bacillus,Mycobacterium influenzae
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013228 Stearates Salts and esters of the 18-carbon saturated, monocarboxylic acid--stearic acid. Octadecanoate,Octadecanoates,Stearate

Related Publications

J P Butzler, and R Vanhoof, and N Clumeck, and P de Mol, and M P Vanderlinden, and E Yourassowsky
May 1983, British dental journal,
J P Butzler, and R Vanhoof, and N Clumeck, and P de Mol, and M P Vanderlinden, and E Yourassowsky
May 1999, Journal of ethnopharmacology,
J P Butzler, and R Vanhoof, and N Clumeck, and P de Mol, and M P Vanderlinden, and E Yourassowsky
January 1971, Antibiotiki,
J P Butzler, and R Vanhoof, and N Clumeck, and P de Mol, and M P Vanderlinden, and E Yourassowsky
June 1958, Oral surgery, oral medicine, and oral pathology,
J P Butzler, and R Vanhoof, and N Clumeck, and P de Mol, and M P Vanderlinden, and E Yourassowsky
March 1967, The Medical annals of the District of Columbia,
J P Butzler, and R Vanhoof, and N Clumeck, and P de Mol, and M P Vanderlinden, and E Yourassowsky
March 1954, A.M.A. archives of internal medicine,
J P Butzler, and R Vanhoof, and N Clumeck, and P de Mol, and M P Vanderlinden, and E Yourassowsky
November 1953, Southern medical journal,
J P Butzler, and R Vanhoof, and N Clumeck, and P de Mol, and M P Vanderlinden, and E Yourassowsky
July 1978, Dental Cadmos,
J P Butzler, and R Vanhoof, and N Clumeck, and P de Mol, and M P Vanderlinden, and E Yourassowsky
March 1987, Journal of the American Academy of Dermatology,
J P Butzler, and R Vanhoof, and N Clumeck, and P de Mol, and M P Vanderlinden, and E Yourassowsky
May 1972, The Journal of laboratory and clinical medicine,
Copied contents to your clipboard!